Why R&D innovation holds the key to greater patient impact

How can innovation in clinical trials drive greater patient impact? BeiGene’s Dr Nils Eckardt and Dr Mieke Borgs highlight how novel systems and ways of working can support the delivery of high-quality medicines faster and more efficiently, helping to deliver greater and faster patient access in Europe. Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. In the EU, an estimated 2.7 million people are diagnosed with cancer annually and the number is growing. With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. However, access to these medicines is not close to meeting patient demand, creating inequalities in the health prospects of those diagnosed with cancer. The picture is similar across many other diseases.